tiprankstipranks

Exscientia and Recursion Merge to Revolutionize Drug Discovery

Exscientia and Recursion Merge to Revolutionize Drug Discovery

Exscientia Plc (EXAI) has released an update.

Confident Investing Starts Here:

Exscientia Plc merges with Recursion to form a powerful AI-driven drug discovery platform, marking a significant step in the industrialization of drug development. This strategic move results in Exscientia becoming a wholly owned subsidiary of Recursion, enhancing their capabilities with over 10 clinical and preclinical programs and potential milestone payments exceeding $20 billion. The merger aims to accelerate drug discovery processes, reduce costs, and introduce innovative treatments faster than traditional methods.

For further insights into EXAI stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App